Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer's Disease

VG-3927 Clinical Trial Progress - VG-3927 demonstrates potential as a differentiated approach to treating Alzheimer's disease (AD) with improved safety and efficacy, addressing multiple aspects of AD pathophysiology [1] - The ongoing Phase 1 trial has enrolled 80 healthy volunteers, with 60 receiving VG-3927 across single ascending dose (SAD) and multiple ascending dose (MAD) cohorts as of June 30, 2024 [1] - Interim data shows VG-3927 achieved a robust decrease in sTREM2 in cerebrospinal fluid (CSF), demonstrating clinical proof-of-target engagement [3] - VG-3927's safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profile supports its continued development as a potential once-daily oral therapy for AD [3][8] - The company plans to report complete Phase 1 data, including data from the AD patient cohort, in Q1 2025 [3][9] VG-3927 Mechanism and Biomarker Data - VG-3927 acts as a TREM2 agonist, converting microglia into a neuroprotective state, supported by preclinical and clinical data [3] - VG-3927 showed a predictable PK profile supportive of once-daily dosing and a sustained decrease in sTREM2 in CSF across SAD and MAD cohorts [5] - Repeat dosing of VG-3927 increased osteopontin/secreted phosphoprotein 1 (SPP1), a biomarker associated with neuroprotective microglia [5] - No effect on soluble Colony Stimulating Factor 1 Receptor (sCSF1R), a microglial trophic factor, has been observed to date [5] Company Strategy and Pipeline - Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases by restoring microglia function [6] - The company's lead candidate, iluzanebart, is a monoclonal antibody targeting TREM2 for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) [6] - VG-3927, a small molecule TREM2 agonist, is being developed for AD and other neurodegenerative diseases associated with microglial dysfunction [6] Upcoming Presentations and Data Releases - Vigil plans to present new preclinical and clinical data from the VG-3927 SAD cohorts at the 2024 Alzheimer's Association International Conference (AAIC) [7][8] - The company has commenced screening for an AD patient cohort in the Phase 1 trial to explore biomarker responses after a single dose of VG-3927 [9]